病例队列设计作为评估COVID-19疫苗有效性、免疫衰减、异源免疫效应和最佳接种间隔的高效方法
在加拿大安大略省2020年12月至2021年10月期间,利用基于人群的病例线和疫苗接种数据库,采用病例队列设计评估SARS-CoV-2疫苗接种后感染风险。结果显示第一剂疫苗有效性68%(95%CI 67%-69%),第二剂88%(95%CI 87-88%),延长接种间隔与突破感染风险最低相关,异源疫苗方案比仅用mRNA疫苗更有效,第二剂后4-6个月感染风险基本消失但之后显著上升。
要点
- 第一剂疫苗有效性68%(95%CI 67%-69%),第二剂88%(95%CI 87-88%)。
- 延长接种间隔与突破感染风险最低相关,6-8周再接种HR为0.64(95%CI 0.61-0.67)。
- 异源疫苗方案(病毒载体疫苗首剂+mRNA第二剂)显著比仅mRNA疫苗更有效。
核心结论
- 病例队列设计能高效实时识别SARS-CoV-2疫苗接种的强保护效应,并量化同一队列中突破感染风险的时间和幅度。
- 异源疫苗接种和延长接种间隔改善了免疫反应的持久性。
研究设计与样本
- 研究结合加拿大安大略省2020年12月至2021年10月期间基于人群的病例线和疫苗接种数据库。
- 采用病例队列设计,评估所有实验室确诊的接种疫苗的SARS-CoV-2病例和2%的接种对照样本。
- 使用生存分析方法,包括构建Cox比例风险模型,疫苗接种状态作为时变协变量。
主要发现
- 第一剂SARS-CoV-2疫苗有效性68%(95%CI 67%-69%),第二剂有效性88%(95%CI 87-88%)。
- 在多变量模型中,延长接种间隔与突破感染风险最低相关,6-8周再接种HR为0.64(95%CI 0.61-0.67)。
- 异源疫苗方案(病毒载体疫苗首剂与mRNA第二剂混合)显著比仅mRNA疫苗更有效。
- 第二剂疫苗接种后4-6个月期间感染风险基本消失,但之后显著上升。
临床怎么用
- 作者认为病例队列设计可高效实时识别SARS-CoV-2疫苗接种的强保护效应。
- 作者认为异源疫苗接种和延长接种间隔改善了免疫反应的持久性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Though widely applied in other epidemiological fields, the case-cohort study design has seen little application in the field of vaccinology. Case-cohort studies use probabilistic sampling and reweighting to draw inferences about effects (in this case vaccine efficacy) at the population level in an efficient manner. The SARS-CoV-2 pandemic was met with high vaccine uptake, and high rates of population testing prior to the emergence of Omicron variants of concern, in Ontario, Canada, providing an ideal environment for application of case-cohort methodology. We combined a population-based case line list and vaccination database for the province of Ontario between December 2020 and October 2021. Risk of infection after vaccination was evaluated in all laboratory-confirmed vaccinated SARS-CoV-2 cases, and a 2 % sample of vaccinated controls, evaluated using survival analytic methods, including construction of Cox proportional hazards models. Vaccination status was treated as a time-varying covariate. First and second doses of SARS-CoV-2 vaccine markedly reduced risk of infection (first dose efficacy 68 %, 95 % CI 67 %-69 %; second dose efficacy 88 %, 95 % CI 87-88 %). In multivariable models, extended dosing intervals were associated with lowest risk of breakthrough infection (HR for redosing 0.64 (95 % CI 0.61-0.67) at 6-8 weeks). Heterologous vaccine schedules that mixed viral vector vaccine first doses with mRNA second doses were significantly more effective than mRNA only vaccines. Risk of infection largely vanished during the time period 4-6 months after the second vaccine dose, but rose markedly thereafter. We conclude that a case-cohort design provided an efficient means to identify strong protective effects associated with SARS-CoV-2 vaccination in real time, and also served to quantify the timing and magnitude of infection breakthrough risk in the same cohort. Heterologous vaccination and extended dosing intervals improved the durability of immune response.
引用
- Fisman DN, Simmons AE, Tuite AR, et al. Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval. Vaccine. 2024. PMID: 39004528. doi:10.1016/j.vaccine.2024.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。